U.S. markets closed

Cronos Group Inc. (CRON)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.9500-0.0100 (-0.51%)
At close: 04:00PM EDT
1.9400 -0.01 (-0.51%)
After hours: 04:29PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.9600
Bid1.9600 x 27000
Ask1.9700 x 1800
Day's Range1.9000 - 1.9800
52 Week Range1.6400 - 3.6160
Avg. Volume2,752,804
Market Cap754.073M
Beta (5Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)-0.3800
Earnings DateNov 06, 2023 - Nov 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.55
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CRON

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cronos Group Inc. Common Share
    Analyst Report: Cronos Group Inc.Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.
    Fair Value
    Economic Moat
    26 days agoMorningstar
View more
  • InvestorPlace

    Hidden Gems: 3 Cannabis Stocks Flying Under the Radar

    Cannabis stocks have navigated an extended period of uncertainty and financial depression thanks to regulatory headwinds. Further, most cannabis companies have witnessed an extended period of cash burn. There is, however, some optimism and I believe that these overlooked cannabis stocks to buy should be considered. The good news is that even without federal level legalization, the cannabis market in the U.S. is likely to be worth $71 billion by 2030. If we consider the European markets, the tota

  • Zacks

    Calliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains?

    Calliditas Therapeutics AB Sponsored ADR (CALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • InvestorPlace

    3 Penny Stocks That Can Still Double Before the End of 2023

    The market year-to-date has been rewarding after the big correction witnessed last year. There are several growth and penny stocks that have bounced back strongly after being decimated last year. While some stocks trade at fair value or are overvalued, there are penny stocks to buy that trade at a valuation gap. This column focuses on the non-speculative penny stocks to buy for 100% returns in the next few months. Of course, the rally depends on a few specific catalysts. If these factors play ou